

**EudraCT number** 2016-001658-16 **Sponsor code** M15-534

**Study Title:** A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Please note the following: Although a EudraCT number was assigned for this trial, the study was prematurely terminated (no subjects enrolled at EU sites). Therefore, AbbVie will not be submitting study results.